Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented a mixed but generally positive outlook. The company achieved positive GAAP net income for the first time, showing profitability. Despite revenue reductions, the confidence in maintaining EBITDA guidance and ongoing margin expansion is promising. The strategic focus on AI, integration of AccessOne, and growth in Network Solutions and organic payments are positive indicators. While there are concerns about client spending and GLP-1 drugs, the overall sentiment and strategic direction suggest a likely positive stock price movement, especially for a small-cap stock with a market cap of $1.2 billion.
Key Financial Performance
Revenue $127.1 million for Q4 FY 2026, up 16% year-over-year. Growth was led by Payment Solutions following the acquisition of AccessOne. Excluding the AccessOne acquisition, revenue was up 7% year-over-year.
Adjusted EBITDA $29.4 million for Q4 FY 2026, compared to $16.4 million in the same period in the prior year, representing an adjusted EBITDA margin of 23%. This reflects significant margin expansion.
Average Healthcare Services Clients (AHSCs) 4,658 for Q4 FY 2026, an increase of 138% from the prior quarter. 80 of these AHSCs were contributed by the AccessOne acquisition.
Total Revenue per AHSC $27,279 for Q4 FY 2026, up 8% year-over-year.
Net Cash Provided by Operating Activities $33.7 million for Q4 FY 2026, up $17.4 million year-over-year. This improvement was driven primarily by changes in working capital and operating cash flows provided by AccessOne.
Free Cash Flow $28.5 million for Q4 FY 2026, up $19.3 million year-over-year, marking the strongest quarterly free cash flow to date.
Cash and Cash Equivalents $73.8 million as of January 31, 2026, compared to $84.2 million as of January 31, 2025. The decrease reflects capital allocation decisions.
Positive GAAP Net Income Achieved for the first time in FY 2026, reflecting the company's evolution into profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Provider Connect: Launched as a first-of-its-kind offering for healthcare provider marketers, extending the proven PatientConnect playbook to providers.
AccessOne: Acquisition central to strategy, providing tools to convert patient receivables into predictable cash flow. Performing in line with expectations and expanding access to capital for securitization programs.
Revenue Growth: Revenue for Q4 FY2026 was $127.1 million, up 16% year-over-year, driven by Payment Solutions and AccessOne acquisition.
HCP Marketing: Scaling HCP marketing offering, leveraging AI and other tools to enhance market presence.
AI Integration: Using AI to automate manual processes, reduce reliance on outsourced resources, and drive efficiency, contributing to margin expansion.
Financial Milestones: Achieved $100 million in adjusted EBITDA, $50 million in free cash flow, and positive GAAP net income for the first time.
Capital Allocation: Refinanced bridge loan with a $275 million senior secured revolving credit facility, prioritizing long-term shareholder value through debt paydown, growth investments, and share repurchases.
Revenue Outlook Adjustment: Lowered FY2027 revenue outlook due to shorter visibility into spending commitments by pharmaceutical manufacturers, reflecting external dynamics rather than structural demand shifts.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Shorter visibility into spending commitments by pharmaceutical manufacturers: Phreesia is experiencing shorter visibility into spending commitments by certain pharmaceutical manufacturers, particularly in the Network Solutions business. This has led to lower levels of committed dollars for the second half of fiscal year 2027, creating variability in revenue forecasting.
Challenges in the healthcare industry: The healthcare industry is facing adversity, including challenges in FDA guidelines, insurance coverage, patient utilization, and provider reimbursement. These external factors could impact Phreesia's operations and financial performance.
Economic uncertainty in Network Solutions revenue: Segments of the life sciences industry are facing challenges, which are reflected in shorter visibility into spending commitments from pharmaceutical manufacturers. This external dynamic is causing variability in financial forecasts for the Network Solutions business.
Dependence on external capital for AccessOne expansion: Phreesia is actively working to expand access to capital for its securitization programs to scale AccessOne solutions. Dependence on external capital could pose a risk to the growth of this initiative.
Revenue growth slowdown: Phreesia has lowered its revenue outlook for fiscal year 2027 due to external dynamics in the Network Solutions business, signaling a more modest revenue growth year.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for Fiscal Year 2027: Revenue is expected to be in the range of $510 million to $520 million, revised down from the prior range of $545 million to $559 million. This adjustment reflects shorter visibility into spending commitments by certain pharmaceutical manufacturers, particularly in the Network Solutions segment.
Adjusted EBITDA Outlook for Fiscal Year 2027: Maintained at $125 million to $135 million, despite the reduced revenue range. This reflects the operating leverage and efficiency gains achieved, including the adoption of artificial intelligence to reduce reliance on manual processes.
AHSC Growth Expectation for Fiscal Year 2027: Anticipated to grow in the mid-single-digit percentage range.
Total Revenue per AHSC for Fiscal Year 2027: Updated to a low single-digit percentage growth range, revised from the previous low double-digit range, due to Network Solutions headwinds.
Capital Allocation Priorities: Following the refinancing of the bridge loan, capital will be allocated to areas enhancing long-term shareholder value, including potential paydown of long-term debt, investments to support revenue growth acceleration, and share repurchases as appropriate.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchases: With the refinancing complete, we intend to prioritize allocation of capital to areas that we believe can enhance long-term shareholder value, which may include the paydown of long-term debt investment to support revenue growth acceleration and share repurchases as appropriate.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the visibility of client spending in the Network Solutions end market?
A:The visibility is fluid and not broad-based. Specific areas like vaccines and public health with federal agencies have seen spending pullbacks. Updates will be provided as the year progresses.
Q:What is the contribution of ProviderConnect to the revenue outlook?
A:ProviderConnect is in its early days and has a very small base. It is not a significant contributor to the revenue outlook at this stage.
Q:How are price negotiations and Medicare drug price renegotiations impacting pharma client budgets?
A:These factors are not directly tied to the revenue outlook, but they do not help with other topics.
Q:What cost actions are being implemented to maintain EBITDA guidance despite revenue reductions?
A:The company is leveraging AI efficiency gains and reducing costs in areas like outsourcing manual processes. Structural cost reductions and margin expansion efforts over the past years are also contributing.
Q:Are sales, marketing, and R&D expenses expected to increase year-over-year?
A:Specific guidance was not provided, but R&D is expected to contribute more to margin expansion in fiscal '27 compared to other areas.
Q:What is causing variability in payment facilitator percentages and payment processing revenue growth?
A:Client activity and better attach rates are causing variability. Payment processing revenue is expected to grow year-over-year in single digits, excluding AccessOne contributions.
Q:What are the priorities for driving growth in AccessOne?
A:The focus is on tighter integration and cross-selling opportunities within Phreesia, as well as expanding AccessOne as a standalone business unit. Expanding the capital base is also a priority.
Q:Is there any revenue concentration in the updated Network Solutions guidance?
A:There is no significant revenue concentration in the updated guidance. Updates will be provided as the year progresses.
Q:How is AI expected to impact the competitive landscape in the software business?
A:AI is increasing the breadth of offerings and value provided to clients. The company believes it is well-positioned to leverage AI for continuous improvement in healthcare.
Q:How are GLP-1 drugs impacting Network Solutions revenue?
A:GLP-1 drugs are categorized as a negative factor for revenue, along with vaccines and public health spending reductions.
Q:What caused the recent worsening of visibility in pharma commitments?
A:The worsening is specific to PatientConnect and not ProviderConnect, which has shown positive developments.
Q:What is the expected growth rate of the three revenue segments in the long term?
A:Network Solutions is expected to grow the fastest, followed by organic payments and then subscription revenue.
Q:How is AccessOne scaling and what are the associated costs?
A:AccessOne is scaling through both existing Phreesia clients and greenfield opportunities. Expanding the capital base is crucial for growth, and incremental costs are expected for scaling.
Q:What is the strategy for subscription pricing and client retention?
A:The strategy focuses on improving existing products and providing more value to clients. The company is proactive and offensive in its approach to client retention.
Q:How is the company addressing the revenue reduction in Network Solutions?
A:The company views the reduction as a speed bump and maintains conviction in its differentiated value proposition.
Q:Why is the company maintaining its EBITDA guidance despite revenue reductions?
A:The company has confidence in its ability to meet or exceed the guidance due to ongoing margin expansion and efficiency improvements.
Q:Why are oral GLP-1 drugs considered a negative factor for Network Solutions?
A:The negative impact is attributed to the broader category of GLP-1 drugs and FDA activity, not specifically to oral formulations.
Q:What is the expected cadence of Network Solutions revenue throughout the year?
A:The revenue impact is expected to be more significant in the second half of the year, with the first half performing better than expected.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on sales, marketing, and R&D expenses, as well as detailed explanations for the negative impact of oral GLP-1 drugs on Network Solutions. Additionally, there was a lack of clarity on the exact contributions of ProviderConnect and AccessOne to the overall revenue outlook.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI role
AccessOne HCP
AccessOne month
AccessOne solution
Conference Phreesia
Connect kind
Connect playbook
FDA guideline
HCP marketing
Mr evening
PatientConnect point
Phreesia evolution
Phreesia foundation
Phreesia mission
Phreesia position
Phreesia variability
Provider Connect
Providers tool
Relations website
Segments life
Solutions dynamic
access affordability
access capital
accomplishment dedication
achievement milestone
challenge
decision one
demand
extension
health care
launch
moment
profile
provider financing
side
strength
PHR Transcript
Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
Positive3-31
The earnings call presented a mixed but generally positive outlook. The company achieved positive GAAP net income for the first time, showing profitability. Despite revenue reductions, the confidence in maintaining EBITDA guidance and ongoing margin expansion is promising. The strategic focus on AI, integration of AccessOne, and growth in Network Solutions and organic payments are positive indicators. While there are concerns about client spending and GLP-1 drugs, the overall sentiment and strategic direction suggest a likely positive stock price movement, especially for a small-cap stock with a market cap of $1.2 billion.
Phreesia, Inc. (PHR) Q3 2026 Earnings Call Transcript
Positive12-8
The earnings call presents strong financial metrics, including consecutive positive net income and increased cash flow, which are positive indicators. The Q&A session highlights a cautious but optimistic outlook, with plans for strategic investments and growth. While some management responses lack clarity, the overall sentiment is positive due to strong cash flow, margin expansion, and growth potential from acquisitions. The market cap suggests a moderate reaction, leading to a positive stock price movement prediction.
Phreesia, Inc. (PHR) Q2 2026 Earnings Call Transcript
Positive9-4
The earnings call summary highlights strong financial metrics, optimistic guidance, and strategic acquisitions like AccessOne, which align with market expansion and product development goals. The Q&A session revealed analyst confidence in AI integration and new product offerings, despite some uncertainty regarding specific revenue details. The company's market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Phreesia, Inc. (NYSE:PHR) Q1 2026 Earnings Call Transcript
Positive5-29
The earnings call indicates strong financial performance with a 15% revenue increase and improved cash flow. Positive free cash flow and a strong cash position, along with a focus on product development, contribute to a positive outlook. Despite concerns about economic factors, management's resilience and strategic focus on growth and shareholder value are reassuring. The Q&A reveals no significant risks or uncertainties, and management's opportunistic share repurchase plan suggests confidence in future performance. Given the company's small-cap status, a positive stock price movement is expected.
PHR Slides
PHR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
